Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.
Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.
Panbela Therapeutics, Inc.已正式要求美國證券交易委員會（SEC）加快其文件編號爲333-276367的S-1表格註冊聲明的生效日期。該請求的日期爲2024年1月25日，是根據經修訂的1933年《證券法》第461條提出的。該公司力求使註冊聲明在東部時間當天下午 5:30 生效，或在此之後儘快生效。這一舉措是爲Panbela Therapeutics擬議的公開發行證券做準備。該公司已承認其根據該法案承擔的與發行有關的責任。有關該加速請求的任何詢問均已轉交給擔任Panbela Therapeutics法律顧問的Faegre Drinker Biddle & Reath LLP的約書亞·科爾本。該信函由Panbela Therapeutics首席財務官蘇珊·霍瓦斯簽署。
Panbela Therapeutics, Inc.已正式要求美國證券交易委員會（SEC）加快其文件編號爲333-276367的S-1表格註冊聲明的生效日期。該請求的日期爲2024年1月25日，是根據經修訂的1933年《證券法》第461條提出的。該公司力求使註冊聲明在東部時間當天下午 5:30 生效，或在此之後儘快生效。這一舉措是爲Panbela Therapeutics擬議的公開發行證券做準備。該公司已承認其根據該法案承擔的與發行有關的責任。有關該加速請求的任何詢問均已轉交給擔任Panbela Therapeutics法律顧問的Faegre Drinker Biddle & Reath LLP的約書亞·科爾本。該信函由Panbela Therapeutics首席財務官蘇珊·霍瓦斯簽署。
有用
沒用
該公告為獨立文件：